Thursday 31 of August, 2023
Group leader positions at Institut Necker Enfants Malades, Université Paris Cité, Paris-France
The Institut Necker Enfants Malades (INEM, https://www.institut-necker-enfants-malades.fr/) invites applications for two group leader positions. Excellent future prospects and an upwards-scientific track record will be the principal selection criteria. We promote equal opportunities, strongly encouraging applications from female candidates and welcome applications from early career scientists as well as established PIs who wish to join INEM.
Candidates should have an innovative research [...]

Monday 3^rd of July, 2023
Summer School on Pharmaceutical medicine (July 3 - 6, 2023)
The school is being developed as part of the TrainCKDis network (Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discovery; www.trainckdis.eu): a European innovative, multidisciplinary, and intersectoral training programme to prepare the next generation of top-level scientists to develop creative solutions for transforming CKD research. The [...]

Wednesday 3^rd of May, 2023 at 12:00
Prestige Lectures at INEM

Hans Clevers is a Dutch molecular geneticist, cell biologist and stem cell researcher. Hans is currently the Head of pharma Research and Early Development (pRED), and a member of the Corporate Executive Committee of F. Hoffmann-La Roche based in Basel, Switzerland. Previously, Hans headed a research group at the Hubrecht Institute for Developmental Biology and Stem Cell Research and at the Princess Máxima Center for Pediatric Oncology and Oncode where he has remained as an advisor and [...]

Monday 24 of April, 2023
Identification of AKT-FoxO1 as an on/off gate for marginal zone B cell development
The team of Simon Fillatreau identified in a collaborative work with the team of Dr. Nadine Hövelmeyer (Mainz University, Germany) the chief role of the AKT-FoxO1 signaling axis in the formation of mouse and human marginal zone B cells, which are involved in host defense against encapsulated bacteria (Cell Reports, doi: 10.1016/j.celrep.2023.112378

Friday 17 of March, 2023
Just published in JCI Insight
Just published in JCI Insight: the team of Marco Pontoglio and the team of Fabiola Terzi, in collaboration with the pathology department of Necker hospital, have elucidated two key events in the pathophysiology of kidney damage in patients with COVID-19: (1) they demonstrated that SARS-CoV-2 infects living renal cells and that the infection is associated with increased death; (2) they showed that SARS-CoV-2 activates specific genetic networks and identified X-linked [...]

Thursday 16 of February, 2023
Exploiter le 5\'super-enhancer de TAL1 dépendant de MYB pour une thérapie ciblée dans la LAL-T.
L'acquisition d'anomalies génétiques entraînant une dérégulation des oncogènes est à la base du développement du cancer. Certains proto-oncogènes possèdent plusieurs mécanismes de dérégulation. Dans la leucémie aiguë lymphoblastique à cellules T (LAL-T), au sein d''équipe de V. Asnafi, Charlotte Smith a montré que les patients porteurs de mutations 5'superenhancer (5'SE) de l'oncogène TAL1 [...]

Thursday 16 of February, 2023
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL
The acquisition of genetic abnormalities engendering oncogene dysregulation underpins cancer development. Certain proto-oncogenes possess several dysregulation mechanisms. In T-cell Acute Lymphoblastic Leukaemia (T-ALL), within the team of V. Asnafi, Charlotte Smith has shown that patients carrying 5’superenhancer (5’SE) mutations of the TAL1 oncogene identifies a specific subgroup of patients associated with poor prognosis, [...]

Wednesday 1^st of February, 2023
Tracing the origin of T-independent responses in humans

Just Published in Science Immunology: Sandra Weller and coll. in the former team of Claude-Agnès Reynaud and Jean-Claude Weill, in collaboration with the group of Pr. Guy Gorochov (CIMI, Paris and AP-HP) investigated the B cell subsets involved in T-independent (TI) responses. Such responses are directed against nonproteins with repeated [...]

Address

Notice: Undefined variable: contact_addr in /homepages/40/d483507699/htdocs/location.php on line 21

Support(s)

HRH Princess Caroline of Hanover, who through the Princess Grace Foundation, already supports medical research and anything that helps to relieve the sick children in France and around the world, has agreed to commit to our side so that our Center of Molecular medicine continues to meet the current challenges and fight diseases, and in particular the ones affecting children.

Legal mentions

INEM - Organigramme